MDWD
MediWound Ltd. · Healthcare
16.93
2.51%(+0.41)
Market OpenLast Updated: — ET
52W L: $14.7752W H: $22.50
$16.93
CHG+0.02 (+0.12%)
H$17.78
L$14.90
VOL1.3M
MDWD (1h)
MediWound Ltd. · Healthcare
MediWound to Present New EscharEx ® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL ® Findings support ongoing VALUE Phase III study and planned expansion into DFUs and pressure ulcers YAVNE, Israel, April 7, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced multiple oral and poster presentations at three leading wound care conferences: the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2026, taking place April 8–12 in Charlotte, North Carolina, and the European Wound Management Association (EWMA) 2026, taking place May 6–8 in Bremen, Germany.
Dyne Therapeutics (NASDAQ: DYN - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings. Profitability This table compares Dyne Therapeutics and MediWound's net
MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation (NASDAQ:VCEL), its exclusive distributor of NexoBrid® in North America, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript
MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5 , 202 6 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t oday announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”) on March 5, 2026.
MediWound (MDWD) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.36 per share a year ago.
Driver Vickie Rae
director
0 SH @ $0.00
2026-03-18
Driver Vickie Rae
director
0 SH @ $0.00
2026-03-18
Driver Vickie Rae
director
14,285 SH @ $12.25
2021-06-29
Driver Vickie Rae
director
1,607 SH @ $37.52
2022-06-15
Driver Vickie Rae
director
5,357 SH @ $14.42
2023-05-16
Driver Vickie Rae
director
5,900 SH @ $11.88
2024-05-31
Driver Vickie Rae
director
7,542 SH @ $12.73
2025-02-26
Driver Vickie Rae
director
5,600 SH @ $18.54
2026-02-11